ASP Isotopes (NASDAQ:ASPI) Stock Price Up 8.1% – Should You Buy?

ASP Isotopes Inc. (NASDAQ:ASPI) rose 8.1% on Friday . The company traded as high as $7.08 and last traded at $6.87. Approximately 607,571 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 1,914,677 shares. The stock had previously closed at $6.36.

ASP Isotopes Price Performance

The stock has a market capitalization of $547.20 million, a price-to-earnings ratio of -11.95 and a beta of 3.40. The company has a 50 day moving average of $5.21 and a 200 day moving average of $5.44. The company has a quick ratio of 7.54, a current ratio of 7.55 and a debt-to-equity ratio of 0.80.

Insider Activity at ASP Isotopes

In related news, COO Robert Ainscow sold 66,666 shares of the company’s stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $5.75, for a total value of $383,329.50. Following the completion of the transaction, the chief operating officer now directly owns 1,553,326 shares in the company, valued at approximately $8,931,624.50. This represents a 4.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Paul Elliot Mann sold 316,666 shares of the company’s stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $5.62, for a total value of $1,779,662.92. Following the completion of the transaction, the chief executive officer now owns 7,315,454 shares of the company’s stock, valued at $41,112,851.48. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 766,667 shares of company stock worth $4,358,502. 21.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ASP Isotopes

Several institutional investors have recently added to or reduced their stakes in ASPI. Barclays PLC increased its stake in ASP Isotopes by 438.5% in the third quarter. Barclays PLC now owns 72,330 shares of the company’s stock valued at $201,000 after purchasing an additional 58,897 shares during the last quarter. JPMorgan Chase & Co. grew its position in ASP Isotopes by 31.4% during the third quarter. JPMorgan Chase & Co. now owns 22,196 shares of the company’s stock valued at $62,000 after acquiring an additional 5,307 shares during the period. SG Americas Securities LLC purchased a new stake in ASP Isotopes during the fourth quarter valued at about $100,000. Hanson & Doremus Investment Management purchased a new stake in ASP Isotopes during the fourth quarter valued at about $27,000. Finally, Almanack Investment Partners LLC. purchased a new stake in ASP Isotopes during the fourth quarter valued at about $68,000. 16.80% of the stock is currently owned by institutional investors and hedge funds.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.